Fast BDNF serum level increase and diurnal BDNF oscillations are associated with therapeutic response after partial sleep deprivation

Journal of Psychiatric Research

Volumn 59, Issue , 2014, Pages 1-7

  Giese, Maria ^a,d   Beck, Johannes ^a   Brand, Serge ^a   Muheim, Flavio ^a   Hemmeter, Ulrich ^b   Hatzinger, Martin ^c   Holsboer Trachsler, Edith ^a   Eckert, Anne ^a,d  

^a UNIVERSITY OF BASEL   (Switzerland)

^b Psychiatric Service Center St Gallen   (Switzerland)

^c Psychiatric Services Solothurn   (Switzerland)

^d UNIVERSITY OF BASEL   (Switzerland)

Author keywords

BDNF; Depression; Sleep deprivation; Therapy response

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; MIANSERIN; MIRTAZAPINE; TRICYCLIC ANTIDEPRESSANT AGENT;

ADULT; AGED; ANTIDEPRESSANT ACTIVITY; ARTICLE; CIRCADIAN RHYTHM; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; HAMILTON SCALE; HUMAN; MAJOR DEPRESSION; MALE; PARTIAL SLEEP DEPRIVATION; PREDICTION; PROTEIN BLOOD LEVEL; SLEEP DEPRIVATION; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; ANALYSIS OF VARIANCE; BLOOD; DEPRESSIVE DISORDER, MAJOR; ENZYME LINKED IMMUNOSORBENT ASSAY; MIDDLE AGED; PHYSIOLOGY; PSYCHOLOGICAL RATING SCALE; QUESTIONNAIRE; TIME; YOUNG ADULT;

ADULT; AGED; ANALYSIS OF VARIANCE; ANTIDEPRESSIVE AGENTS, TRICYCLIC; BRAIN-DERIVED NEUROTROPHIC FACTOR; CIRCADIAN RHYTHM; DEPRESSIVE DISORDER, MAJOR; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MIANSERIN; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; QUESTIONNAIRES; SLEEP DEPRIVATION; TIME FACTORS; YOUNG ADULT;

EID: 84908353899     PISSN: 00223956     EISSN: 18791379     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2014.09.005     Document Type: Article

References (50)

1. Autry A.E., Adachi M., Nosyreva E., Na E.S., Los M.F., Cheng P.F., et al. NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature 2011, 475:91-95.
2. Bech P., Gram L.F., Dein E., Jacobsen O., Vitger J., Bolwig T.G. Quantitative rating of depressive states. Acta Psychiatr Scand 1975, 51:161-170.
3. Beck J., Hemmeter U., Brand S., Muheim F., Hatzinger M., Holsboer-Trachsler E. Modafinil reduces microsleep during partial sleep deprivation in depressed patients. JPsychiatr Res 2010, 44:853-864.
4. Begliuomini S., Lenzi E., Ninni F., Casarosa E., Merlini S., Pluchino N., et al. Plasma brain-derived neurotrophic factor daily variations in men: correlation with cortisol circadian rhythm. JEndocrinol 2008, 197:429-435.
5. Berman R.M., Cappiello A., Anand A., Oren D.A., Heninger G.R., Charney D.S., et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 2000, 47:351-354.
6. Brunoni A.R., Amadera J., Berbel B., Volz M.S., Rizzerio B.G., Fregni F. Asystematic review on reporting and assessment of adverse effects associated with transcranial direct current stimulation. Int J Neuropsychopharmacol 2011, 1-13.
7. Conti B., Maier R., Barr A.M., Morale M.C., Lu X., Sanna P.P., et al. Region-specific transcriptional changes following the three antidepressant treatments electro convulsive therapy, sleep deprivation and fluoxetine. Mol Psychiatry 2007, 12:167-189.
8. Dell'Osso L., Del Debbio A., Veltri A., Bianchi C., Roncaglia I., Carlini M., et al. Associations between brain-derived neurotrophic factor plasma levels and severity of the illness, recurrence and symptoms in depressed patients. Neuropsychobiology 2010, 62:207-212.
9. Duman R.S. Role of neurotrophic factors in the etiology and treatment of mood disorders. Neuromol Med 2004, 5:11-25.
10. Duman R.S., Aghajanian G.K. Neurobiology of rapid acting antidepressants: role of BDNF and GSK-3beta. Neuropsychopharmacology 2014, 39:233.
11. Duman R.S., Heninger G.R., Nestler E.J. Amolecular and cellular theory of depression. Arch Gen Psychiatry 1997, 54:597-606.
12. Duman R.S., Li N. Aneurotrophic hypothesis of depression: role of synaptogenesis in the actions of NMDA receptor antagonists. Philos Trans R Soc Lond Ser B Biol Sci 2012, 367:2475-2484.
13. Duman R.S., Malberg J., Nakagawa S., D'Sa C. Neuronal plasticity and survival in mood disorders. Biol Psychiatry 2000, 48:732-739.
14. Duman R.S., Monteggia L.M. Aneurotrophic model for stress-related mood disorders. Biol Psychiatry 2006, 59:1116-1127.
15. Faraguna U., Vyazovskiy V.V., Nelson A.B., Tononi G., Cirelli C. Acausal role for brain-derived neurotrophic factor in the homeostatic regulation of sleep. JNeurosci 2008, 28:4088-4095.
16. Fujimura H., Altar C.A., Chen R., Nakamura T., Nakahashi T., Kambayashi J., et al. Brain-derived neurotrophic factor is stored in human platelets and released by agonist stimulation. Thromb Haemost 2002, 87:728-734.
17. Giedke H., Schwarzler F. Therapeutic use of sleep deprivation in depression. Sleep Med Rev 2002, 6:361-377.
18. Giese M., Unternaehrer E., Brand S., Calabrese P., Holsboer-Trachsler E., Eckert A. The interplay of stress and sleep impacts BDNF level. PLoS One 2013, 8:e76050.
19. Giese M., Unternahrer E., Huttig H., Beck J., Brand S., Calabrese P., et al. BDNF: an indicator of insomnia?. Mol Psychiatry 2014, 19:151-152.
20. Gold P.W., Chrousos G.P. Organization of the stress system and its dysregulation in melancholic and atypical depression: high vs low CRH/NE states. Mol Psychiatry 2002, 7:254-275.
21. Haile C.N., Murrough J.W., Iosifescu D.V., Chang L.C., Al Jurdi R.K., Foulkes A., et al. Plasma brain derived neurotrophic factor (BDNF) and response to ketamine in treatment-resistant depression. Int J Neuropsychopharmacol 2014, 17:331-336.
22. Hairston I.S., Peyron C., Denning D.P., Ruby N.F., Flores J., Sapolsky R.M., et al. Sleep deprivation effects on growth factor expression in neonatal rats: a potential role for BDNF in the mediation of delta power. JNeurophysiol 2004, 91:1586-1595.
23. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967, 6:278-296.
24. Holsboer-Trachsler E., Seifritz E. Sleep in depression and sleep deprivation: a brief conceptual review. World J Biol Psychiatry 2000, 1:180-186.
25. Holsboer-Trachsler E., Stohler R., Hatzinger M. Repeated administration of the combined dexamethasone-human corticotropin releasing hormone stimulation test during treatment of depression. Psychiatry Res 1991, 38:163-171.
26. Holsboer F., Barden N. Antidepressants and hypothalamic-pituitary-adrenocortical regulation. Endocr Rev 1996, 17:187-205.
27. Karege F., Bondolfi G., Gervasoni N., Schwald M., Aubry J.M., Bertschy G. Low brain-derived neurotrophic factor (BDNF) levels in serum of depressed patients probably results from lowered platelet BDNF release unrelated to platelet reactivity. Biol Psychiatry 2005, 57:1068-1072.
28. Karege F., Schwald M., Cisse M. Postnatal developmental profile of brain-derived neurotrophic factor in rat brain and platelets. Neurosci Lett 2002, 328:261-264.
29. Katoh-Semba R., Tsuzuki M., Miyazaki N., Matsuda M., Nakagawa C., Ichisaka S., et al. Aphase advance of the light-dark cycle stimulates production of BDNF, but not of other neurotrophins, in the adult rat cerebral cortex: association with the activation of CREB. JNeurochem 2008, 106:2131-2142.
30. Kendler K.S., Karkowski L.M., Prescott C.A. Causal relationship between stressful life events and the onset of major depression. Am J Psychiatry 1999, 156:837-841.
31. Lee B.H., Kim H., Park S.H., Kim Y.K. Decreased plasma BDNF level in depressive patients. JAffect Disord 2007, 101:239-244.
32. Lee H.Y., Kim Y.K. Plasma brain-derived neurotrophic factor as a peripheral marker for the action mechanism of antidepressants. Neuropsychobiology 2008, 57:194-199.
33. Li N., Lee B., Liu R.J., Banasr M., Dwyer J.M., Iwata M., et al. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 2010, 329:959-964.
34. Liang F.Q., Walline R., Earnest D.J. Circadian rhythm of brain-derived neurotrophic factor in the rat suprachiasmatic nucleus. Neurosci Lett 1998, 242:89-92.
35. Liu R.J., Fuchikami M., Dwyer J.M., Lepack A.E., Duman R.S., Aghajanian G.K. GSK-3 inhibition potentiates the synaptogenic and antidepressant-like effects of subthreshold doses of ketamine. Neuropsychopharmacology 2013, 38:2268-2277.
36. Molendijk M.L., Bus B.A., Spinhoven P., Penninx B.W., Kenis G., Prickaerts J., et al. Serum levels of brain-derived neurotrophic factor in major depressive disorder: state-trait issues, clinical features and pharmacological treatment. Mol Psychiatry 2011, 16:1088-1095.
37. Murrough J.W., Iosifescu D.V., Chang L.C., Al Jurdi R.K., Green C.E., Perez A.M., et al. Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. Am J Psychiatry 2013, 170:1134-1142.
38. Okamoto T., Yoshimura R., Ikenouchi-Sugita A., Hori H., Umene-Nakano W., Inoue Y., et al. Efficacy of electroconvulsive therapy is associated with changing blood levels of homovanillic acid and brain-derived neurotrophic factor (BDNF) in refractory depressed patients: a pilot study. Prog Neuropsychopharmacol Biol Psychiatry 2008, 32:1185-1190.
39. Pan W., Banks W.A., Fasold M.B., Bluth J., Kastin A.J. Transport of brain-derived neurotrophic factor across the blood-brain barrier. Neuropharmacology 1998, 37:1553-1561.
40. Piccinni A., Marazziti D., Catena M., Domenici L., Del Debbio A., Bianchi C., et al. Plasma and serum brain-derived neurotrophic factor (BDNF) in depressed patients during 1 year of antidepressant treatments. JAffect Disord 2008, 105:279-283.
41. Pluchino N., Cubeddu A., Begliuomini S., Merlini S., Giannini A., Bucci F., et al. Daily variation of brain-derived neurotrophic factor and cortisol in women with normal menstrual cycles, undergoing oral contraception and in postmenopause. Hum Reprod 2009, 24:2303-2309.
42. Sartorius A., Hellweg R., Litzke J., Vogt M., Dormann C., Vollmayr B., et al. Correlations and discrepancies between serum and brain tissue levels of neurotrophins after electroconvulsive treatment in rats. Pharmacopsychiatry 2009, 42:270-276.
43. Shimizu E., Hashimoto K., Okamura N., Koike K., Komatsu N., Kumakiri C., et al. Alterations of serum levels of brain-derived neurotrophic factor (BDNF) in depressed patients with or without antidepressants. Biol Psychiatry 2003, 54:70-75.
44. Shirayama Y., Chen A.C., Nakagawa S., Russell D.S., Duman R.S. Brain-derived neurotrophic factor produces antidepressant effects in behavioral models of depression. JNeurosci 2002, 22:3251-3261.
45. Soumier A., Banasr M., Lortet S., Masmejean F., Bernard N., Kerkerian-Le-Goff L., et al. Mechanisms contributing to the phase-dependent regulation of neurogenesis by the novel antidepressant, agomelatine, in the adult rat hippocampus. Neuropsychopharmacology 2009, 34:2390-2403.
46. Tadic A., Wagner S., Schlicht K.F., Peetz D., Borysenko L., Dreimuller N., et al. The early non-increase of serum BDNF predicts failure of antidepressant treatment in patients with major depression: a pilot study. Prog Neuropsychopharmacol Biol Psychiatry 2011, 35:415-420.
47. Warner-Schmidt J.L., Duman R.S. Hippocampal neurogenesis: opposing effects of stress and antidepressant treatment. Hippocampus 2006, 16:239-249.
48. Wittchen U., Zaudig M., Schramm E., Spengler P., Mombour W., Klug J., et al. Strukturiertes klinisches interview für DSM-III-R. Deutschsprachige erweiterte Bearbeitung der amerkikanischen Originalversion des SCID 1987, Beltz-Test, Weinheim. V.R.L. Spitzer, J.B.W. Williams, M. Gibbon (Eds.).
49. Wolkowitz O.M., Wolf J., Shelly W., Rosser R., Burke H.M., Lerner G.K., et al. Serum BDNF levels before treatment predict SSRI response in depression. Prog Neuropsychopharmacol Biol Psychiatry 2011, 35:1623-1630.
50. Zarate C.A., Singh J.B., Carlson P.J., Brutsche N.E., Ameli R., Luckenbaugh D.A., et al. Arandomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 2006, 63:856-864.